After years of dispute with FDA, Vanda will get a public hearing for jet lag drug

RegulatoryPositive

AI Analysis

Summary

The FDA has agreed to hold a rare formal evidentiary public hearing for Vanda Pharmaceuticals regarding its sleep disorder drug, which the agency had previously rejected. This represents a significant regulatory development after years of dispute between the company and the FDA.

Outcome Details

FDA agreed to hold a formal evidentiary public hearing for Vanda's sleep disorder drug following prior rejection

Importance:7/10

Sentiment:

0.60

FDA rejectionpublic hearingsleep disorderregulatory dispute

Related Companies

$VNDA

Read the original article

Published by Endpoints News on March 3, 2026 8:21 PM

Read Original